Podcast Episodes

Back to Search
Geoff Cook (Noom CEO) - The future of compounded GLP-1s
Geoff Cook (Noom CEO) - The future of compounded GLP-1s

In Episode 44 of Hims House, hosts Jonathan Stern and Patrick Lester (Bayside) sit down with Geoff Cook, CEO of Noom. Noom is one of Hims' competitor…

10 months, 1 week ago

Short Long
View Episode
Dr. William Seeds - WTF are peptides? Are they legal? And where does Hims fit in?
Dr. William Seeds - WTF are peptides? Are they legal? And where does Hims fit in?

In Episode 43 of Hims House, hosts Jonathan Stern and Patrick Lester (Bayside) sit down with Dr. William Seeds, a board-certified orthopedic surgeon …

10 months, 2 weeks ago

Short Long
View Episode
Shaun Noorian (Empower Pharmacy CEO) - GLP-1s, Patents, and the Future of Compounding
Shaun Noorian (Empower Pharmacy CEO) - GLP-1s, Patents, and the Future of Compounding

In Episode 42 of Hims House, Jonathan Stern and Patrick Lester (Bayside) sit down with Shaun Noorian, founder & CEO of Empower Pharmacy, the world’s …

10 months, 3 weeks ago

Short Long
View Episode
Peter Pitts - The Wild West of Compounded GLP-1s
Peter Pitts - The Wild West of Compounded GLP-1s

In this episode of Hims House, Jonathan Stern and Patrick Lester (“Bayside”) sit down with Peter Pitts, president of the Center for Medicine in the P…

11 months ago

Short Long
View Episode
Hims & Hers Q2 2025 Earnings Recap
Hims & Hers Q2 2025 Earnings Recap

In episode 40 of Hims House, Jonathan and Patrick Lester (Bayside) dive into HIMS' Q2 2025 earnings — the company’s first-ever miss vs. Wall Street e…

11 months, 1 week ago

Short Long
View Episode
Ep 39 - Legendary Wall Street analyst David Maris on why Hims could be massive—and what could go wrong
Ep 39 - Legendary Wall Street analyst David Maris on why Hims could be massive—and what could go wrong

In Episode 39 of Hims House, Jonathan Stern and Patrick Lester (Bayside) sit down with David Maris—one of the most decorated healthcare analysts of t…

11 months, 3 weeks ago

Short Long
View Episode
Ep 38 - HIMS WEEK IN REVIEW: Bloomberg, WaPo, Canada, Blood Tests, Nighthawk, and 38% Short Interest 🤯
Ep 38 - HIMS WEEK IN REVIEW: Bloomberg, WaPo, Canada, Blood Tests, Nighthawk, and 38% Short Interest 🤯

In Episode 38 of Hims House, Jonathan Stern and Patrick Lester (Bayside) break down all the recent news surrounding Hims. They cover the new Bloomber…

11 months, 4 weeks ago

Short Long
View Episode
Ep 37 - Top Patent Attorney Explains Why Novo Nordisk Is UNLIKELY to Sue Hims
Ep 37 - Top Patent Attorney Explains Why Novo Nordisk Is UNLIKELY to Sue Hims

Thanks to our partner, Godel Terminal — a full trading terminal at less than 10% of the price of a Bloomberg! CLICK HERE to get 25% off your first mo…

1 year ago

Short Long
View Episode
Ep 36 - Adam May: The Bear Case on HIMS, GLP-1s, Legal Risk, and the Collapse of the Novo Deal
Ep 36 - Adam May: The Bear Case on HIMS, GLP-1s, Legal Risk, and the Collapse of the Novo Deal

In Episode 36 of Hims House, Jonathan Stern and Patrick Lester (aka Bayside) sit down with biotech investor and dermatologist Adam May, easily the mo…

1 year ago

Short Long
View Episode
Ep 35 - Hims x ZAVA: Deep Dive ft. European Healthcare Experts, Sekander Amini + Mads Christiansen
Ep 35 - Hims x ZAVA: Deep Dive ft. European Healthcare Experts, Sekander Amini + Mads Christiansen

Thanks to our partner, Godel Terminal — a full trading terminal at less than 10% of the price of a Bloomberg! CLICK HERE to get 25% off your first mo…

1 year ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us